P Soulié

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

Henri Roché, P. Fumoleau, M. Spielmann et al. · Journal of Clinical Oncology · 2006 · 570 citations · Full text

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Josep Tabernero, Eric Van Cutsem, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2007 · 337 citations

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

M Forni, M C Malet-Martino, P Jaillais et al. · Journal of Clinical Oncology · 1992 · 334 citations

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance

Alain Morel, M. Boisdron‐Celle, Luc Fey et al. · Molecular Cancer Therapeutics · 2006 · 234 citations · Full text